E Therapeutics (GB:ETX) has released an update.
E-Therapeutics plc, known for its RNAi medicine discovery platform, announces today as the last trading day for its shares on AIM, with trading to commence on the JP Jenkins securities matching platform from May 9, 2024. The company encourages shareholders to stay informed through email updates and indicates SP Angel Corporate Finance LLP will no longer serve as its broker post-cancellation. E-Therapeutics continues to progress its computational and RNAi-driven drug discovery, targeting diseases with high unmet needs.
For further insights into GB:ETX stock, check out TipRanks’ Stock Analysis page.
